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ABSTRACT 
The classical approach for delivery of drugs into the central nervous 
system (CNS) is associated with adverse effects and it has many 
limitations. Therefore, extensive efforts have been done in searching 
and developing novel methods for achieving such delivery. This mini-
review discusses the design and synthesis of selected targeting 
prodrugs for the treatment of conditions related to impairment in the 
CNS such as Parkinson‘s and Alzheimer‘s diseases. Such approaches 
include targeting prodrugs which are designed to interact with unique 
cellular conditions at the target site, especially the availability of 
certain enzymes and transporters at these sites. In addition, part of this 
mini-review is devoted to prodrugs design based on enzyme models 
that have been invoked to understand how enzymes  
catalyzebiotransformation. In this approach, the prodrugs design isdone using quantum 
molecular orbital and molecular mechanics methods. The equations obtained from 
correlations of experimental and calculated rate values for some intramolecular processes are 
used to predict parameters for other intramolecular processes that can be utilized as prodrugs 
linkers.  In this approach, there is no need for enzymes to catalyze the conversion of the 
prodrug to its active parent drug and the conversion rate of the prodrug is dependent only on 
those factors playing dominant role in the rate-limiting step of the process. 
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INTRODUCTION 
During the last few decades the percentage of elderly population has drastically increased due 
to an improvement and advancement in the health care system in the developed world. This 
resulted in an increase in the conditions of CNS diseases such as Parkinson‘s and 
Alzheimer‘s which possess a serious public problem. An inefficient treatment for these 
neurodegenerative diseases is caused partly by the physiology of the CNS where the blood 
brain barrier (BBB) secures the entry of any foreign substance including medicines to the 
brain.  Furthermore, the blood-cerebrospinal fluid barrier (BCSFB) is considered the second 
physiological barrier that separates the brain from its blood supply and controls the passage 
of endogenous and exogenous substances. 
 
The BBB contains tight-junctions which only permit the transport of hydrophobic molecules 
to traverse it by diffusion or if the substance is a substrate for DBB carrier mediated 
transporters, also transcytosis takes place which can be absorptive mediated or receptor 
mediated transcytosis.
[1] 
The BBB presents an efficient structural and functional barrier for 
the delivery of therapeutics to the CNS. Due to its unique properties, passage across the BBB 
often becomes the main limiting factor for the delivery of potential CNS medicines into the 
brain parenchyma. In fact, it is estimated that more than 98% of drugs with small-molecular 
weight and practically 100% of drugs having large-molecular weight developed for the CNS  
diseases do not readily cross the BBB.
[2] 
 
There are four factors that play a dominant role in the drugs‘ passage (free diffusion of 
molecules across the BBB) to the brain: hydrogen-bond donors, hydrogen-bond acceptors, 
molecular weight (MW) and partition coefficient (logP). The molecular weight of a drug is 
considered the most important parameter which determines free diffusion of molecules across 
the BBB. Studies have shown that most of the targeted drugs to the CNS have a molecular 
weight of 400-500 Da.
[3]
 It is believed that the pores created in the phospholipid bilayers are 
of limited size and allow only small molecules with a spherical volume that fit into these 
pores. 
[4]
 The second factor determining the passage through BBB is the number of hydrogen-
bond donors which the drug can make through its passage; each pair of hydrogen bonds 
decreases the permeability through DBB by one log of magnitude and it was demonstrated 
that drugs having up to five hydrogen-bond donors are capable of penetrating the BBB 
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whereas those possess higher hydrogen bonds are likely to be blocked from penetration.
[5-6] 
The third parameter determining the drug‘s passage via BBB is the drug‘s plasma 
pharmacokinetics; the drug‘s concentration in the brain is proportional to the BBB 
permeability coefficient (pe) and the drug‘s plasma area under the curve (AUC). Generally, 
increasing the lipophilicity of a drug results in an increase of the Pe but a decrease in the 
plasma AUC, and these factors can have offsetting effects, resulting in little change in the 
drug‘s brain concentration.[7] 
 
For improving the bioavailability of a drug and increase its permeation through the DBB the 
prodrug approach has the potential and capability for achieving such goals. 
 
The classical or traditional prodrugs approach aims to improve the physicochemical 
properties of a drug such as solubility and absorption by attaching the drug moiety to a non-
toxic promoiety by a covalent bond. The resulting prodrug moiety is intended to be cleaved 
inside the body non-specifically or specifically by certain enzymes to give rise to the active 
parent drug. The promoiety can be hydrophilic aiming to increase the drug‘s solubility in 
gastro-intestinal tract (GIT) or hydrophobic aiming to enhance the drug‘s membrane 
permeability. These prodrugs suffer from non-specific activation at sites other than the active 
site resulting in related toxicities and low bioavailability.
[8-10] 
 
On the other hand, targeted prodrugs are synthesized to deliver the desired drugs to a certain 
organ or tissues in the body, thus, overcoming problems associated with the classical 
prodrugs approach. The targeted prodrugs approach achieves its aim depending on the 
presence of unique cellular conditions at the desired target, especially the availability of 
certain enzymes and transporters.  Targeted prodrugs in which a chemical moiety is attached 
to a parent drug to selectively target an activating enzyme or transporter is considered the 
main cornerstone for making efficient clinical profiles. 
 
A successful targeting prodrug must be transported to its site rapidly, cleaved there 
selectively and retained at the site of action for a reliable time.
[11] 
 
Targeting using both enzymes and transporters requires a great knowledge of the molecular 
structure and functionalities of those transporters and enzymes. When synthesizing a prodrug 
to target a specific site in the body, the prodrug must contain a chemical moiety that is 
specifically recognized by the aimed enzyme or transporter which is usually present 
exclusively or overexpressed at the desired site of action.
[12-15] 
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In the last few decades many advances have been made for achieving better CNS delivery. 
Among the approaches used are nanoparticles, liposomes, and some invasive strategies such 
as BBB disruption and intracerebral implants.
[16] 
 
CNS targeting via prodrugs is considered a pharmacological strategy. Classical prodrugs are 
inactive chemical entities which are usually made to improve the physicochemical properties 
of a certain drug. Prodrugs become activated chemically or enzymatically giving rise to the 
active parent drug. When considering prodrugs to target CNS the first thing to come in mind 
is to link the active parent drug to a lipophilic moiety such as fatty acid, glyceride or 
phospholipids which yields a prodrug moiety with the capability to penetrate the BBB. 
Regardless of achieving a successful entry of the drug into the CNS via this approach many 
disadvantages are to be faced including poor selectivity, poor retention time and creation of 
toxic-reactive metabolites.
[17] 
 
Another method used for CNS targeting is the vector mediated delivery. The principle of this 
method relies on using a non-transportable drug conjugated to BBB transport vector. The 
vector can be a modified protein or receptor specific antibody. The vector gains access to the 
brain through BBB transporters (for modified proteins) or via receptor mediated transcytosis 
(for monoclonal antibodies).
[18] 
The active parent drug can be conjugated to the vector via 
different methods such as chemical linkers, avid in-biotin technology, polyethylene glycol 
linkers and liposomes.
[19] 
 
Furthermore, chemical delivery systems are also used in which at least one bond needs to be 
cleaved in order to release the active parent drug. Redox chemical delivery systems have 
shown a satisfactory efficiency in CNS targeting. This method consists of two steps: (i) target 
promoting moiety which is responsible for site specificity and (ii) modifier functions which 
enhance the system lipophilicity; these modifier functions are designed to prevent any 
chemical conversion to unwanted metabolites. Among these chemical delivery systems are 
those depending on an enzymatic oxidation reaction for the conversion of the lipophilic 
dihydropyridine to ionic pyridinium salt, thus retaining the drug in the brain for a longer 
time.
[16] 
 
1- OPIATES PRODRUGS 
Using the redox chemical delivery approach one system was applied for enkephalin delivery 
to the brain. Enkephalins are naturally occurring opioids used as analgesics and can replace 
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the currently used morphine and alkaloids derivatives and thus minimize their associated side 
effects.
[20]
 However, the use of this approach might encounter serious problems since 
enkephalins being proteins make them vulnerable to degradation by peptidases and in 
addition being high hydrophilic compounds limits their blood brain barrier (BBB) 
permeability.
[21] 
 
A strategy to overcome and resolve this problem was achieved by utilizing the prodrug 
approach. An enkephalin prodrug was made with improved in vivo stability. This prodrug is 
δ opioid receptor-selective enkephalin analogue, Tyr-D-Ala-Gly-Phe-D-Leu (DADLE); it is a 
stable chemical entity however it cannot cross the BBB because of its hydrophilic character.
 
[22]
 For overcoming the barrier associated with the hydrophilic nature of this prodrug, brain-
targeting chemical delivery system (BTCDS) for DADLE was made. This system is inactive 
on its own but is enzymatically activated in the brain by peptidases activation. This system 
consists of lipophilic 1, 4-dihydrotrigonellyl moiety which is attached to the N terminus of 
the active parent drug through a peptidic spacer. In the brain, oxidoreductases oxidize the 
dihydropyridine into the positively charged N-methylpyridinium thus retaining the drug in 
the brain for a longer time. 
[23]
 Then the active parent drug is released followed the action of 
several peptidases especially the enzyme prolyloligopeptidase (POP) which removes the 
spacer from the oxidized BTCDS (Figure 1).
[24]
 In vitro studies on rats brain homogenates 
have shown increased half-life of the drug which was correlated with in vivo analgesic effects 
using tail-flick model.
[25] 
 
 
Figure 1: DADLE brain targeting delivery system. (a) DADLE (b) peptidic spacer (c) 
lipophilic 1, 4-dihydrotrigonellyl moiety (d) N-methylpyridine moiety. 
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Morphine, a member of the morphinan-framed alkaloids present in the poppy plant, is a 
potent opioid analgesic widely used for the treatment of acute and long-term treatment of 
severe pain. It is soluble in aqueous media, but has a poor solubility in lipids. In human, 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) are the major 
metabolites of morphine.
[26]
 On the other hand, codeine is considered a morphine prodrug 
since it undergoes oxidative demethylation by cytochrome P450 CYP2D6 to yield morphine 
(Figure 2). Detailed studies on the metabolism of codeine have showed that about 80% of the 
drug is converted to codeine-6-glucuronide, a metabolite that is pharmacologically active 
and, on a dose basis, elicits approximately 60% of the analgesic effect of codeine itself. 
Moreover, less than 5% of the codeine dose is generally converted to morphine. The 
remaining approximately 15% is demethylated by CYP3A4 to norcodeine, which is less 
potent than morphine. From these results, it has been proposed that codeine-6-glucuronide is 
the agent responsible for most of the analgesic effect of codeine, in which case codeine is 
might be considered as a prodrug of the glucuronide metabolite rather than of morphine.
[27] 
Therefore, cytochrome CYP2D6 is necessary for much of the analgesic effect of codeine. 
Most Caucasians convert codeine to morphine via CYP2D6 as other population around the 
world. However, approximately 7% - 10% of Caucasians have a genetic variant that produces 
limited CYP2D6 activity and slow metabolism of CYP2D6 substrates. In these cases, 
interconversion of codeine to morphine is reduced resulting in less analgesic efficacy. Upon 
administration of codeine dosage forms to these persons the expected extent of analgesia 
which is achieved will be drastically reduced.  
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Figure 2: Conversion of codeine to its glucuronide and morphine metabolites with 
higher biological activity. 
 
Wang et al. have synthesized two N-alkyl esters of morphine, morphine propionate and 
morphine enanthate as potential prodrugs for transdermal delivery of morphine (Figure 3). 
Both prodrugs were found to be more lipophilic than their parent drug. The in vitro skin 
permeation of morphine and its prodrugs, morphine propionate and morphine enanthate, 
showed that both prodrugs enhanced the transdermal delivery of morphine by 2- and 5-fold, 
respectively.
[28]
 The enhanced delivery might be due to the lipophilic nature of the prodrugs 
which enable permeation through membranes barriers especially BBB. 
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Figure 3: Chemical structures for N-alkyl esters of morphine, morphine propionate and 
morphine enanthate. 
 
In another study conducted by Ward et al. on two newly synthesized ester prodrugs of 
morphine, Morphine Prodrug A and Morphine Prodrug B, which are esterase-sensitive 
prodrugs demonstrated that complexation with dendrimer allowed the solubilization of the 
prodrugs for in vivo applications without the necessity for salt. In addition, the structural 
features of the morphine prodrugs allowed the release of morphine in a controlled manner 
which extended the analgesic effect of morphine in an animal pain model from 2 hours for 
the control to 6 hours upon using Morphine Prodrug A (Figure 4).
[29]
  
 
 
Figure 4: Chemical structures for morphine ester prodrugs, MP Prodrug A and MP 
Prodrug B. 
 
The main obstacle of peptides delivery to the brain its hydrophilic character and sensitivity to 
cleavage by peptidases found within the capillary endothelium.
[30]  
 
The esterase activation approach is considered as one of the main approaches to deliver drugs 
into the brain. Among the most promising examples of such approach is the one involves the 
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glycine derivative, thiorphan, a neutral endopeptidase inhibitor (Figure 5). The endopeptidase 
is a metalloenzyme responsible together with aminopeptidase N for the inactivation of 
endogenous enkephalins. The use of thiorphan encounters permeation restriction due to its 
inability to cross the BBB.
[31]
 On the other hand, some of its thiol derivatives such as S-
acetylthiorphan (Figure 5), the monoacylated form of thiorphan, and acetorphan (Figure 5), 
the benzyl ester of S-acetylthiorphan, have proven to possess high analgesic effect, 
suggesting that their enhanced lipophilicity improves BBB permeation. Once these entities 
enter the brain they undergo hydrolysis catalyzed by esterase to the more active inhibitor 
thiorphan, 1. 
[32-33]
 Study that has been done by Fournie-Zaluski et al.
[34]
 revealed that the 
benzyl ester of acetorphan undergoes rapid hydrolysis in serum and therefore the metabolite 
S-acetylthiorphan is accountable for the BBB penetration.  
 
Later on, based on the conclusions revealed from Fournie-Zaluski study  Lambert and 
coworkers.
[35]
 have made a series of  prodrugs consisting of amide pseudo triglycerides of S-
acetylthiorphan in which the ester linkages in positions 1 and 3 of the glyceride have been 
replaced with amide linkages aiming to increase their metabolic stability. Pain tests have 
showed that these new compounds exhibited superior analgesic effects to those of thiorphan 
and S-acetylthiorphan, suggesting that they were acting as prodrugs. 
 
More recent study in which the esterase activation was utilized to transport drugs through the 
BBB into the brain is the one reported by Krause et al.
[36]
 on azomethine prodrugs of (R)-α-
methylhistamine (Figure 6). Krause‘s study demonstrated a correlation between lipophilicity 
and passive diffusion into the brain.  The study also revealed that the release of the active 
parent drug is achieved after a chemical hydrolysis in which the carbon-nitrogen double bond 
is cleaved. 
 
 
Figure 5: Chemical structures of thiorphan and prodrugs of thiorphan 
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Figure 6: Chemical structures of azomethine prodrugs of (R)-α-methylhistamine. 
 
2- GABAPENTIN PRODRUGS 
Gabapentin, 1-(aminomethyl)cyclohexaneacetic acid, has similar chemical structure to 
GABA (Figure 7), and is used as anticonvulsant in various seizure models. Furthermore, 
gabapentin was approved for the treatment of trigeminal neuralgia, post herpetic neuralgia 
and other neuropathic pain status as it displays anti-nociceptive activity in various animal 
pain models. 
[37-38]
 Gabapentin is also effective in improving restless legs syndrome (RLS) 
suggesting a potential role in treating this disease. 
[37]
 Gabapentin‘s absorption occurs in the 
small intestine by a combination of diffusion and facilitated transports. Its transport from the 
gut is carried out by a saturable l-amino acid transport mechanism. The bioavailability of 
gabapentin varies inversely with dose as the carrier-dependent transport is saturable, and 
therefore the bioavailability of a 300-mg dose is approximately 60%, whereas that of a 600-
mg dose is approximately 40%. Its Cmax increases less than threefold as a result of the dose-
dependent saturable absorption, when the dose is tripled from 300 to 900 mg.
[39] 
 
However, more interestingly, XP13512 ((±)-1-([(α-isobutanoyloxyethoxy) carbonyl]-
aminomethyl)-1-cyclohexane acetic acid) (Figure 7) a novel transported prodrug of 
gabapentin was developed to overcome the pharmacokinetic deficiencies of gabapentin. 
XP13512 is a novel transported prodrug of gabapentin that is absorbed throughout the entire 
length of the intestine by high-capacity nutrient transporters. XP13512 is stable in 
gastrointestinal contents and is actively absorbed after oral dosing by high-capacity nutrient 
transporters present throughout the intestinal tract.
[40-41]
 Following absorption, the prodrug is 
rapidly converted to gabapentin by nonspecific esterases. During conversion to gabapentin, 
each molecule of XP13512 also generates one molecule of each of the following: carbon 
dioxide, acetaldehyde and isobutyrate.
[40-41]
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Overall, XP13512 may provide enhanced absorption, more predictable gabapentin exposure, 
reduced interpatient variability, and decreased dosing frequency compared with commercial 
gabapentin. Therefore, XP13512 has the potential to become an important option for the 
management of long-term neuropathies and other conditions currently treated with oral 
gabapentin.
[40-41] 
 
An alternative strategy was employed by Polli and coworkers where gabapentin was coupled 
to a natural substrate for a transporter to yield several novel prodrugs. These prodrugs were 
strategically designed to target hASBT with the same high affinity and high capacity as 
native bile acids. Among the five newly synthesized prodrugs, two were found to be potential 
prodrugs that may increase gabapentin absorption via hASBT uptake: CDCA-glu-gabapentin 
methyl ester and CDCA-gabapentin. The inhibition study with taurocholate revealed that the 
gabapentin conjugates are potent inhibitors, with strong interaction with the transporter. 
The Km and Vmax values for both prodrugs demonstrate high transporter affinity and capacity. 
The normalized Vmax showed hASBT to possess higher transporter capacity for these two 
conjugates than for the native bile acid taurocholate. Furthermore, both prodrugs were 
chemically stable however; they underwent catalyzed-degradation to the active parent drug. 
Based on this study the researchers concluded that these two conjugates are novel prodrugs of 
gabapentin and can be designed to target hASBT.
[42] 
 
H2N
O
OH
N
H O
OH
OO
O
Gabapentin
XP13512  
Figure 7: Chemical structures of gabapentin and XP13512. 
 
3- DOPAMINE PRODRUGS 
Dopamine is a neurotransmitter produced in the body and activates the five types of 
dopamine receptors– D1, D2, D3, D4, and D5 found in the brain. Dopamine is also a 
neurohormone released by the hypothalamus to inhibit the release of prolactin from the 
anterior lobe of the pituitary. The dopamine main functions are to regulate movement, 
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emotion, motivation, and the feeling of pleasure. Shortage of dopamine as a result of the 
death of dopamine neurons causes Parkinson‘s disease (PD), in which the ability to execute 
smooth and controlled movements is diminished. Since dopamine cannot cross the blood–
brain barrier (BBB), it is not given as a drug for Parkinson‘s disease. To increase the amount 
of dopamine in the brains of patients with diseases such as Parkinson's disease and dopa-
responsive dystonia, levodopa (LD), which is the precursor of dopamine, is administered 
since it can cross the BBB.
[43-44]
  
 
The current therapy for PD is essentially symptomatic. L-dopa, the direct precursor of 
dopamine, is still the best choice of treatment for PD. However, long-term therapy with L-
dopa is associated with significant adverse effects.
[45]
 PD patients have insufficient dopamine 
in specific regions of the brain, but since dopamine doesn't cross the BBB and its precursor 
LD does patients of this disease were given large doses of levodopa to compensate the 
deficiency of dopamine in the brain. However, because much of the LD is decarboxylated to 
dopamine in the periphery, high doses of LD are required, resulting in side effects that 
include nausea, vomiting, cardiac arrhythmias, and hypotension.
[46]
 To minimize the 
conversion of LD to DA outside the CNS, LD is usually co- administered with peripheral 
inhibitors of amino acid decarboxylase such as carbidopa and benserazide.
[47-48] 
Although 
treatment with LD has minimized some side effects, other CNS adverse effects such as 
dyskinesia, on-off phenomenon and end-of-dose deterioration still remain.  
 
It should be emphasized that the major factors causing the poor bioavailability of LD and 
inter- and intra-patient variations of plasma levels are the LD physicochemical properties 
such as the low water and lipid solubility which leads to unfavorable partition, and the high 
susceptibility to chemical and enzymatic degradation.
[47] 
 
Recently, several attempts have been made to develop LD prodrugs with improved 
pharmacological and pharmacokinetic properties.
[47]
 For PD treatment, in addition to LD, DA 
agonists, antimuscarinic drugs, monoamine oxidase (MAO)-B and amantadine were utilized 
in Parkinson‘s disease. [49-51]The following text describes the different prodrug approaches to 
enhance DP bioavailability and its concentrations in the brain.  
 
3.1. Lipophilic LD prodrugs 
A respected number of LD derivatives, such as ester, amide, dimeric and cyclic prodrugs, 
have been designed and made to increase LD lipophilicity: 
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3.1.1 Ester prodrugs 
Nine ester derivatives of LD were the first to be synthesized as potentially LD prodrugs with 
enhanced bioavailability.
[52-60] 
 
Although these prodrugs were as effective as their parent active drug, LD, in providing motor 
activity, however, none of them was significantly more potent or has longer duration than 
LD.
[58]
 On the other hand, two highly soluble ester prodrugs of LD and therapeutically 
efficient were synthesized, a methyl (Levomet, Chiesi Pharmaceuticals, Parma-Italy) and an 
ethyl ester (etilevodopa, TV-1203, Teva Pharmaceuticals, Petah Tikva-Israel).
[61]
 The ethyl 
ester, which is currently in Phase III clinical trials, could be given SC or IM for rigidity and 
to reverse akinesia. Studies showed that this prodrug was tolerated with only minor and 
negligible adverse effects.
[62]
 In addition, its physicochemical properties, such as water 
solubility and lipophilicity were found to be superior to those of LD and may hold promise 
for development of delivery strategies that would not be feasible with LD.  
 
3.1.2 Amide prodrugs 
Another approach which has been utilized to increase lipophilicity and thereby enhance the 
penetration through BBB to the brain is making LD amide prodrugs which are expected to 
undergo slower hydrolysis than their corresponding ester prodrugs. Novel LD amide prodrugs 
(1 in Figure 8) for the treatment of PD and other similar conditions were patented.
[63]
 On the 
other hand, Jiang et al. have synthesized the LD amide prodrug 2 (Figure 8), and studied the 
in vivo (rats) release of LD from the prodrug after it underwent enzymatic hydrolysis 
following oral administration. 
[64]
 The in vivo analysis for the amide prodrug and LD, 
respectively are: the Cmax was 1980.7 ± 538.5 and 1936.6 ± 114.6 ng/ml, the Tmax was 24.5 ± 
3.5 and 4.5 ± 0.8 min, the area under curve (AUC) was 217,158.9 ± 70,832.1 and 94,469.5 ± 
7183.0 ng/ml min and the t½ was 56.5 ± 14.4 and 30.6 ± 1.6 h. 
 
3.1.3 Dimeric prodrugs 
Dimeric prodrugs can be made by direct attachment of two identical molecules or by linking 
the two identical molecules through a spacer.
[65-69]
 Felix and coworkers have made LD dimer 
prodrugs without spacer,
[70]
 while Di Stefano and coworkers have synthesized a number of 
dimeric prodrugs with different spacers.
[71-74] 
All the synthesized dimers were stable in 
aqueous buffer solution (pH 1.3 and 7.4) and in human plasma they liberate the LD in a slow 
release manner. Moreover, after per os administration, the DA concentration decreased much 
more slowly than that achieved with LD administration.  
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3.1.4 Cyclic prodrugs 
A number of cyclic LD prodrugs were made by substituting the LD carboxyl and the amine 
groups in a cyclic skeleton. Based on this strategy, Cingolani and coworkers have prepared 
the l-3-(3-hydroxy- 4-pivaloyloxybenzyl)-2,5-diketomorpholine (3 in Figure 8), in which the 
2,5-diketomorpholine ring was essential for enhancing the stability toward GI hydrolysis and 
to liberate LD in human plasma after enzyme-catalyzed hydrolysis.
[75] 
 
3.1.5 Chemical delivery system 
Ishikura et al. has obtained a specific CDS for the brain delivery of LD (LD-CDS) by 
esterification of the protected carboxylic group of LD with a thiazolium moiety.
[76]
  
 
Ishikura brain delivery system is based on the redox ring closing reaction of cis-2-
formylaminoethenylthio derivatives to quaternary thiazolium derivatives and the drug release 
was followed after hydrolysis of the ester bond. IV administration of these prodrugs and an 
equimolar dose of LD in rats revealed that while LD plasma levels did not show any 
difference between animals injected with prodrugs and those injected with LD, the LD levels 
in the whole brain were higher after prodrug administration compared with LD 
administration. 
 
3.2 Lipophilic DA prodrugs 
3.2.1 Ester prodrugs 
DA is not used in PD treatment since it undergoes complete ionization at physiological pH, 
resulting in poor permeation across the BBB and other cell membranes. To overcome these 
problems, Casagrande et al. and Borgman et al. have prepared a number of lipophilic 3,4-O-
diesters prodrugs of DA as potential latentiated lipophilic derivatives of DA to be used in the 
therapy of PD, hypertension and renal failure.
[77-78] 
The results by Borgman et al. showed that 
O-acetylation was not enough to provide entry into the CNS while retaining intrinsic 
dopaminergic activity and N-alkylation of the DA molecule are also required.
[78]
  
 
3.2.2 Chemical delivery system 
Similar to that done for LD, chemical drug delivery systems for brain-specific delivery have 
also been designed and made for DA.
[79]
 These prodrug devices were made joining DA with a 
pyridinium/dihydropyridine redox carrier.
[80-81] 
This carrier enables the prodrug entity to 
penetrate the BBB and then be oxidized to a quaternary precursor that is retained in the CNS, 
to provide a DA sustained release form. 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                            
            
 
222
Rafik et al.                                   World Journal of Pharmacy and Pharmaceutical Sciences 
3.2.3 Peptide transport-mediated prodrugs 
2-Amino- N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide (DOPH), an amide 
prodrug of DA,  was prepared by Giannola et al. (4 in Figure 8).
[82]
 upon condensation of DA 
with a neutral amino acid to interact with the BBB endogenous transporters and smoothly 
penetrate into the brain. DOPH underwent a slow cleavage by cerebral enzymes (t½ 460 min) 
and produced free DA in the CNS; however, in human plasma it underwent a rapid hydrolysis 
(t½ 28 min). In addition, chemical stability of DOPH showed the prodrug to be completely 
stable in the gastrointestinal tract and was able to permeate through a simulated intestinal 
mucosal membrane.  
 
In another study, More and Vince synthesized prodrug (5 in Figure 8) in which DA is linked 
covalently via an amide bond to GSH.
[83]
 Compound 5 (Figure 8) showed high affinity for the 
GSH transporter at the BBB, liberated DA at the target site and showed a pretty good stability 
balance between the periphery and brain.  
 
3.2.4 GLUT1 carrier-mediated prodrugs 
Fernandez and coworkers designed and synthesized glycoconjugates in which the amino 
group of DA was attached to C-6, C-3 and C-1 of the sugar through a succinyl linker, 
carbamate bond, glycosidic and ester bonds. The prodrugs‘ affinity for the glucose carrier 
GLUT1 was tested using human erythrocytes.
[84-85] 
Upon incubation with brain extracts, 
several prodrugs liberated DA in rates that were found to be largely affected by the nature of 
the bond between DA and glucose. The glycosyl conjugates substituted at the C-6 position of 
the sugar were more potent inhibitors of glucose transport compared with C-1 and C-3 
substituted prodrugs. In another study, Bonina et al. and Ruocco et al. have prepared sugar-
DA prodrugs in which DA was attached to C-3 position of glucose (6 in Figure 8) and to C-6 
of galactose (7 in Figure 8) by a succinyl spacer. Both of these prodrugs were found to be 
more active than LD in reversing reserpine-induced hypolocomotion in rats.
[86-87]
 
 
Although some success has been achieved using the different approaches by which prodrugs 
of DA and LD were utilized to provide DA in adequate concentrations and sustained release 
manner the prodrug chemical approach involving enzyme catalysis has many disadvantages 
related to many intrinsic and extrinsic factors that can affect the process. For instance, the 
activity of many prodrug-activating enzymes may be varied due to genetic polymorphisms, 
age-related physiological changes, or drug interactions, leading to variation in clinical effects. 
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Therefore, there is a need to synthesize new prodrugs for the treatment of Parkinson's disease 
having higher bioavailability than the current medications,
[88-94]
 and have the potential to 
release DA in a sustained manner via intramolecular chemical conversion without a need for 
enzyme catalysis.
[88] 
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Figure 8: Chemical structures of compounds 1-7. 
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In the past seven years Karaman‘s group have explored a number of intramolecular processes 
to gain insight into enzyme catalysis and at the same time to utilize these enzyme models for 
the development of prodrug linkers with improved bioavailability over existing 
medications.
[95-144]  
 
Few years ago we have designed and synthesized a number of DA prodrugs for the treatment 
of Parkinson‘s disease having the potential to be with a higher bioavailability than the current 
medications. The designed prodrugs have the following physicochemical properties: (i) 
soluble in physiological environment (ii) possess moderate hydrophilic lipophilic balance 
(HLB) (iii) release DA in a controlled manner, and (iv) undergo chemical cleavage to non-
toxic by-products.
[88] 
 
Utilizing enzyme models as potential linkers to be linked to amine-drugs, we have explored 
the proton transfer reaction in some of Kemp‘s acid amide derivatives, 8-18 (Figure 9). [96] 
Based on the DFT calculations of the proton transfer mechanism of these acid amides, two 
dopamine prodrugs were proposed. As illustrated in Figure 10, ProD 1 and ProD 2 have a 
moderate HLB. In addition, in the blood circulation (pH 7.4) the dominant form of dopamine 
is the ionized form while prodrugs ProD 1-2 are expected to exist in both forms, the ionic 
and the free acid. Thus, it is expected that prodrugs ProD 1-2 may have a better 
bioavailability than DA because of improved absorption. Further, the designed prodrugs can 
be administered in a variety of dosage forms (i.e. enteric coated tablets) since they are 
expected to be soluble in organic and aqueous media due to the ability of the COOH to 
convert to COO- in physiological environments of pH 5.0-7.4 (intestine and blood 
circulation(. 
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Figure 9. Chemical structures of Kemp’s acid amides 8-18. 
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    Figure 10: DA prodrugs ProD 1- ProD 2. 
 
Moreover, the computational calculations predict a t1/2 value of the cleavage reactions of 
ProD 1- ProD 2 at pH 6 to be 12-20 hours, whereas at pH 7 the value is expected to be 
higher. The strategy to provide prodrugs for the treatment of Parkinson‘s disease with 
improved bioavailability consists of: (i) synthesis of Kemp‘s amide acid  linker and linking it 
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with DA according to Menger‘s synthetic method [130]; (ii) in vitro kinetic studies of ProD 
1- ProD 2 in physiological environment (37 °C, pH = 6.0 in aqueous medium) and (iii) for 
the prodrugs that demonstrate desirable programmed release in the in vitro studies, in vivo 
pharmacokinetic studies should be carried out in order to determine the bioavailability and 
the duration of action of the tested prodrugs                                                               .           
 
SUMMARY AND CONCLUSIONS 
In the past few years, researchers have shifted their attention towards developing targeted 
prodrugs to replace currently marketed drugs with poor bioavailability and insufficient 
clinical profiles. The targeted prodrugs approach has been accelerated after encouraging 
results which were emerged from a respected number of studies on targeted prodrugs that 
demonstrated better efficiency and higher safety profiles. 
 
In this mini review targeted drugs delivery to the CNS using prodrugs is covered. Methods 
for targeting disease and selected newly synthesized prodrugs are reported in details. Many of 
the listed prodrugs in this mini review are still in clinical studies hoping to pass all clinical 
phases and be approved for marketing. 
 
During the last two decades a significant advances have been for better delivery of drugs into 
the brain ( CNS) Among these used methods are nanoparticles, liposomes, and some invasive 
strategies such as BBB disruption and intracerebral implants  
 
Generally, prodrugs targeting the CNS are made by linking the active parent drug to a 
lipophilic moiety such as fatty acid, glyceride or phospholipids which is capable to permit 
BBB transmission. Regardless of the achievement of successful entry of the drug into the 
CNS via this method many disadvantages are to be faced including poor selectivity, poor 
retention and the creation of toxic/reactive metabolites. 
 
An interesting strategy to solve the problems associated with the current targeting prodrugs is 
the one we suggested by us in which an active drug is linked to enzyme model 
(intramolecular chemical device) and upon an exposure of the prodrug moiety to the blood 
circulation within the brain it undergoes intramolecular chemical conversion (without any 
involvement of enzymes) to the active parent drug in a controlled manner. The conversion 
rate of the prodrug to its parent drug is solely determined on the chemical features of the 
linker (enzyme model (.  
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